文献速递血液净化与透析水电解质与酸碱

磷酸盐转运体泛抑制剂AP306在血液透析患者中的应用

A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.
PubMed 文献 · Kidney Int Rep · 2025-02-03

这项2期随机对照开放标签研究纳入血清磷酸盐5.5-9.0 mg/dl的血液透析患者,比较AP306与碳酸司维拉姆治疗12周的效果。AP306使血清磷酸盐较基线下降2.51 mg/dl(95%CI:-3.07至-1.92;P<0.001),碳酸司维拉姆下降1.08 mg/dl(95%CI:-1.58至-0.59),AP306组达到KDIGO推荐范围的比例约高20%。

要点

  • AP306单药可显著降低血透患者血清磷酸盐水平
  • AP306组达到KDIGO推荐范围的比例较司维拉姆组约高20%
  • AP306最常见不良事件为胃肠道反应,多为轻中度腹泻

核心结论

  • AP306单药治疗显著降低血液透析高磷血症患者的血清磷酸盐水平,并大幅提高血清磷酸盐控制率。
  • AP306安全且耐受性良好。

研究设计与样本

  • 2期随机、活性对照、开放标签研究,纳入血清磷酸盐5.5-9.0 mg/dl的血液透析患者。
  • 27例随机接受AP306,28例随机接受碳酸司维拉姆,治疗12周。
  • AP306起始75 mg口服每日三次,每4周逐步调整至125 mg和150 mg,以维持血清磷酸盐3.5-5.5 mg/dl。
  • 碳酸司维拉姆按相同标准和频率调整剂量。
  • 主要结局为从基线至治疗结束的血清磷酸盐水平变化。

主要发现

  • 治疗结束时,AP306组血清磷酸盐较基线下降2.51 mg/dl(95%CI:-3.07至-1.92;P<0.001)。
  • 碳酸司维拉姆组血清磷酸盐较基线下降1.08 mg/dl(95%CI:-1.58至-0.59)。
  • 从治疗第5周起,AP306组达到KDIGO推荐范围(2.5-4.5 mg/dl)的患者比例较司维拉姆组约高20%。
  • AP306最常见不良事件为胃肠道疾病(51.9%),多为轻中度腹泻(44.4%)。

关键数值与推荐

  • 入组血清磷酸盐范围:5.5-9.0 mg/dl。
  • AP306剂量调整目标:维持血清磷酸盐3.5-5.5 mg/dl。
  • KDIGO推荐血清磷酸盐目标范围:2.5-4.5 mg/dl。

临床怎么用

  • 对于血液透析高磷血症患者,AP306可作为降低血清磷酸盐并提高达标率的治疗选择。
  • 使用AP306时需关注胃肠道不良反应,尤其是腹泻。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hyperphosphatemia in patients undergoing dialysis is not well-controlled. AP306 is a pan-inhibitor of phosphate transporters, designed to block the active uptake of phosphate through the gastrointestinal tract. METHODS: In this phase 2 randomized, active-controlled, open-label study, hemodialysis patients with serum phosphate between 5.5 and 9.0 mg/dl were randomized to receive either AP306 or sevelamer carbonate for 12 weeks. The primary outcome was the change in serum phosphate levels from baseline until the therapy ceased. AP306 was initiated at 75 mg and adjusted stepwise to 125 mg and 150 mg orally thrice daily every 4 weeks, to maintain serum phosphate between 3.5 and 5.5 mg/dl. Sevelamer levels were adjusted using the same criteria and frequency. RESULTS: A total of 27 patients were randomized to receive AP306 and 28 to receive sevelamer. At the end-of-treatment, both AP306 and sevelamer resulted in a significant decrease from baseline in serum phosphate by 2.51 mg/dl (95% confidence interval [CI]:-3.07 to -1.92; P < 0.001) and 1.08 mg/dl (95% CI: -1.58 to -0.59), respectively. The proportions of patients achieving the recommended range as per the Kidney Disease: Improving Global Outcomes guidelines (2.5-4.5 mg/dl) were about 20% higher in AP306 than in sevelamer, starting from treatment week 5. The most reported adverse events (AEs) associated with AP306 were gastrointestinal disorders (51.9%), most of which were mild to moderate diarrhea (44.4%). CONCLUSION: AP306 monotherapy significantly reduced serum phosphate levels and substantially improved the serum phosphate control rate in hemodialysis patients with hyperphosphatemia. AP306 was safe and well-tolerated.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Wang L, Zuo L, Shi M, et al. A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients. Kidney Int Rep. 2025. PMID: 40303220. doi:10.1016/j.ekir.2025.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。